Back to Search
Start Over
Decreased CD8+ Lymphocytic Infiltration in Multifocal and Multicentric Glioblastomas
- Source :
- Frontiers in Oncology, Vol 11 (2021)
- Publication Year :
- 2021
- Publisher :
- Frontiers Media SA, 2021.
-
Abstract
- PurposeMultifocal and multicentric glioblastomas (mGBMs) are associated with a poorer prognosis compared to unifocal glioblastoma (uGBM). The presence of CD8+ tumor-infiltrating lymphocytes (TILs) is predictive of clinical outcomes in human malignancies. Here, we examined the CD8+ lymphocytic infiltration in mGBMs.MethodsThe clinical data of 57 consecutive IDH wildtype primary mGBM patients with histopathological diagnoses were retrospectively reviewed. CD8+ TILs were quantitatively evaluated by immunohistochemical staining. The survival function of CD8+ TILs was assessed by Kaplan–Meier analysis and Cox proportional hazard models.ResultsNo significant difference in the concentration of CD8+ TILs was observed among foci from the same patient (P>0.150). The presence of CD8+ TILs was similar between multifocal and multicentric GBMs (P=0.885). The concentration of CD8+ TILs was significantly lower in mGBMs than in uGBMs (P=0.002). In mGBM patients, the CD8+ TIL level was associated with preoperative KPS (P=0.018). The median overall survival (OS) of the 57 mGBMs was 9 months. A low CD8+ TIL level (multivariate HR 4.404, 95% CI 1.954-9.926, P=0.0004) was an independent predictor of poor OS, while postoperative temozolomide chemotherapy (multivariate HR 6.076, 95% CI 2.330-15.842, P=0.0002) was independently associated with prolonged OS in mGBMs.ConclusionsDecreased CD8+ TIL levels potentially correlate with unfavorable clinical outcome in mGBMs, suggesting an influence of the local immuno-microenvironment on the progression of mGBMs.
- Subjects :
- Cancer Research
medicine.medical_specialty
medicine.medical_treatment
chemical and pharmacologic phenomena
chemotherapy
Gastroenterology
Internal medicine
Overall survival
Multifocal glioma
Medicine
RC254-282
tumor-infiltrating lymphocytes (TILs)
Chemotherapy
Lymphocytic infiltration
Temozolomide
business.industry
Significant difference
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
hemic and immune systems
CD8
medicine.disease
Oncology
Immunohistochemistry
prognosis
business
medicine.drug
Glioblastoma
Subjects
Details
- ISSN :
- 2234943X
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Frontiers in Oncology
- Accession number :
- edsair.doi.dedup.....89951985d1229687152e0163d0868747
- Full Text :
- https://doi.org/10.3389/fonc.2021.748277